<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00506415</url>
  </required_header>
  <id_info>
    <org_study_id>CENA713D2340</org_study_id>
    <nct_id>NCT00506415</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline</brief_title>
  <official_title>A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Comparative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm^2 Patch in Patients With Mild to Moderate Alzheimer's Disease (AD) Showing Functional and Cognitive Decline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to support the optimal use of rivastigmine patch in long-term
      treatment of Alzheimer's Disease in patients demonstrating functional and cognitive decline
      at the target maintenance dose of rivastigmine patch 10 cm^2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period</measure>
    <time_frame>Baseline and week 48 of double blind period</time_frame>
    <description>The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) subscale comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period</measure>
    <time_frame>Baseline and week 48 of double blind period</time_frame>
    <description>The Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) is a 16 item subscale of the caregiver-based ADCS-IADL scale, developed for the use in dementia studies. The ADCS-IADL total score ranges from 0 to 56, with higher scores indicating less severe impairment. A positive change indicates an improvement from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period</measure>
    <time_frame>390 days was the maximum</time_frame>
    <description>Functional decline was defined by either an at least 1 point decrease in the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) subscale score in a visit and confirmed by the following visit/assessment or at least 2 points decrease from the double blind randomization baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period</measure>
    <time_frame>Baseline and week 48 of double blind period</time_frame>
    <description>Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part A. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. The TMT part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. The score represents the amount of time required to complete the task. Total values for TMT part A range between 0 and 300 seconds. A negative change indicates an improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period</measure>
    <time_frame>Baseline and week 48 of double blind period</time_frame>
    <description>Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part B. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. TMT has two parts: Part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. Task requirements are similar for TMT-Part B except the person must alternate between numbers and letters. Total values for TMT part B range between 0 and 420 seconds. A negative change from baseline indicates an improvement in condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period</measure>
    <time_frame>Baseline and week 48 of double blind period</time_frame>
    <description>Change from baseline to week 48 as assessed by the Neuropsychiatric Inventory (NPI)-10 total score. The scale consists of 10 domains that are rated for both frequency (range 1-4) and severity (range 1-3). A composite score for each domain is calculated (frequency x severity) which ranges from 1 to 12. There is a leading question for each item. If the symptom is not present then the frequency, severity and distress scores are not completed. In this case the score is 0 for the item. The sum of the composite scores yields the NPI-10 total score (range 0-120). A negative change in score indicates an improvement from baseline (symptom reduction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events</measure>
    <time_frame>30 days after a maximum of 96 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1584</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Open label: Rivastigmine (5 cm^2 / 10 cm^2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double blind: Rivastigmine (10 cm^2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double blind: Rivastigmine (15 cm^2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended open label Rivastigmine (10 cm^2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine 5 cm^2</intervention_name>
    <description>5 cm^2 transdermal patch</description>
    <arm_group_label>Open label: Rivastigmine (5 cm^2 / 10 cm^2)</arm_group_label>
    <other_name>Exelon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine 10 cm^2</intervention_name>
    <description>10 cm^2 transdermal patch.</description>
    <arm_group_label>Open label: Rivastigmine (5 cm^2 / 10 cm^2)</arm_group_label>
    <arm_group_label>Double blind: Rivastigmine (10 cm^2)</arm_group_label>
    <arm_group_label>Extended open label Rivastigmine (10 cm^2)</arm_group_label>
    <other_name>Exelon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivastigmine 15 cm^2</intervention_name>
    <description>15 cm^2 transdermal patch.</description>
    <arm_group_label>Double blind: Rivastigmine (15 cm^2)</arm_group_label>
    <other_name>Exelon®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to 15 cm^2 patch</intervention_name>
    <description>Placebo of rivastigmine transdermal patch 15 cm^2.</description>
    <arm_group_label>Double blind: Rivastigmine (10 cm^2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to 10 cm^2 patch</intervention_name>
    <description>Placebo of rivastigmine transdermal patch 10 cm^2.</description>
    <arm_group_label>Double blind: Rivastigmine (15 cm^2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients between 50 and 85 years of age with a diagnosis of probable
             Alzheimers Disease,

          -  Baseline Mini-Mental State Examination (MMSE) score 10-24 inclusive,

          -  A primary caregiver willing to accept responsibility for supervising treatment,
             assessing the patient's condition throughout the study, and for providing input into
             efficacy assessments.

          -  For double blind only: Meet the decline criteria of functional (as assessed by the
             investigator) and cognitive (assessed by a 1 point reduction in Mini-Mental State
             Examination) score between visits or a 3 point reduction from baseline) decline at
             weeks 23, 36 or 48.

        Exclusion Criteria:

          -  Presence of an advanced, severe, progressive, or unstable disease of any type that
             could interfere with efficacy and safety assessments or put the patient at particular
             risk,

          -  Any medical or neurological condition other than Alzheimers Disease that could explain
             the patient's dementia,

          -  A diagnosis of probable or possible vascular dementia,

          -  A current diagnosis of unsuccessfully-treated depression, or any other mental disorder
             that may interfere with the evaluation of the patient's response to study medication,

          -  A history or current diagnosis of cerebrovascular disease (e.g. stroke),

          -  A current diagnosis of severe or unstable cardiovascular disease (e.g. unstable
             coronary artery disease).

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Carson</city>
        <state>California</state>
        <zip>90746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>La Habra</city>
        <state>California</state>
        <zip>90631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80524</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Sunrise</city>
        <state>Florida</state>
        <zip>33351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341-4155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Flushing</city>
        <state>Michigan</state>
        <zip>48433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Roseville</city>
        <state>Michigan</state>
        <zip>48066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <zip>49684-2340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Flemington</city>
        <state>New Jersey</state>
        <zip>08822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Nutley</city>
        <state>New Jersey</state>
        <zip>07110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Somerset</city>
        <state>New Jersey</state>
        <zip>08873</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210-1853</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Morganton</city>
        <state>North Carolina</state>
        <zip>28655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103-4019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009-1957</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Greensburg</city>
        <state>Pennsylvania</state>
        <zip>15601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Beaufort</city>
        <state>South Carolina</state>
        <zip>29902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <zip>37027-5240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Greenfield Park</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Peterborough</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Regina</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Winnipeg</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Fains Veel</city>
        <state>Alsace Lorraine</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Dijon</city>
        <state>Burgundy</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Reims</city>
        <state>Champagne-Ardenne</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Bourg en Bresse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Cherbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Rodez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Bad Neustadt/Saale</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Burg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Duesseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Krefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Muenster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Nuernberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Stralsund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Arcugnano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Città di Castello</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Cremona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>La Spezia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Rho</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Biel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis investigative site</name>
      <address>
        <city>Mendrisio</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>July 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2007</study_first_posted>
  <results_first_submitted>May 1, 2012</results_first_submitted>
  <results_first_submitted_qc>September 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 19, 2012</results_first_posted>
  <last_update_submitted>September 17, 2012</last_update_submitted>
  <last_update_submitted_qc>September 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's</keyword>
  <keyword>Patch</keyword>
  <keyword>Cognitive</keyword>
  <keyword>Decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivastigmine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1,584 participants were enrolled, 1582 received study drug during the initial open label period; of these, 567 were qualified to enter a double blind randomized period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Initial Open Label: Rivastigmine (5 cm^2 / 10 cm^2)</title>
          <description>Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.</description>
        </group>
        <group group_id="P2">
          <title>Double Blind: Rivastigmine (10 cm^2)</title>
          <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
        </group>
        <group group_id="P3">
          <title>Double Blind: Rivastigmine (15 cm^2)</title>
          <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
        </group>
        <group group_id="P4">
          <title>Extended Open Label (10 cm^2)</title>
          <description>Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks (from week 48 to week 96) open label treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Initial Open Label (Maximum 48 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1584">Enrolled patients.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed to Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1582"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1085"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory value</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure results</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problem</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double Blind (Maximum 48 Weeks )</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="286">1 patient was randomized in error and did not receive study drug, hence excluded from this arm.</participants>
                <participants group_id="P3" count="280"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="203"/>
                <participants group_id="P3" count="207"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition no longer requires study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extended Open Label (Maximum 48 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="457">Two participants did not receive study drug, hence excluded from this arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="395"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="62"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unsatisfactory therapeutic effect</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Total Patients</title>
          <description>Total number of patients enrolled in the initial open label period that may have been randomized in the double blind period or may have continued in the extended open label period.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1584"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.93" spread="7.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period</title>
        <description>The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) subscale comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline.</description>
        <time_frame>Baseline and week 48 of double blind period</time_frame>
        <population>Intent to treat population double blind (ITT-DB): included all randomized patients who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables: Alzheimer's Disease Assessment Scale-Cognitive and Disease Cooperative Study-Instrumental Activities of Daily Living.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Blind: Rivastigmine (10 cm^2)</title>
            <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
          <group group_id="O2">
            <title>Double Blind: Rivastigmine (15 cm^2)</title>
            <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Subscale at Week 48 of Double Blind Period</title>
          <description>The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) subscale comprises 11 items summed to a total score ranging from 0 to 70, with lower scores indicating less severe impairment. A negative change indicates an improvement from baseline.</description>
          <population>Intent to treat population double blind (ITT-DB): included all randomized patients who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables: Alzheimer's Disease Assessment Scale-Cognitive and Disease Cooperative Study-Instrumental Activities of Daily Living.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="7.49"/>
                    <measurement group_id="O2" value="4.1" spread="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period</title>
        <description>The Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) is a 16 item subscale of the caregiver-based ADCS-IADL scale, developed for the use in dementia studies. The ADCS-IADL total score ranges from 0 to 56, with higher scores indicating less severe impairment. A positive change indicates an improvement from baseline.</description>
        <time_frame>Baseline and week 48 of double blind period</time_frame>
        <population>Intent to treat population double blind (ITT-DB): included all randomized patients who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables: Alzheimer's Disease Assessment Scale-Cognitive and Disease Cooperative Study-Instrumental Activities of Daily Living.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Blind: Rivastigmine (10 cm^2)</title>
            <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
          <group group_id="O2">
            <title>Double Blind: Rivastigmine (15 cm^2)</title>
            <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale Score From Baseline to Week 48 of Double Blind Period</title>
          <description>The Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) is a 16 item subscale of the caregiver-based ADCS-IADL scale, developed for the use in dementia studies. The ADCS-IADL total score ranges from 0 to 56, with higher scores indicating less severe impairment. A positive change indicates an improvement from baseline.</description>
          <population>Intent to treat population double blind (ITT-DB): included all randomized patients who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables: Alzheimer's Disease Assessment Scale-Cognitive and Disease Cooperative Study-Instrumental Activities of Daily Living.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="8.78"/>
                    <measurement group_id="O2" value="-4.4" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period</title>
        <description>Functional decline was defined by either an at least 1 point decrease in the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) subscale score in a visit and confirmed by the following visit/assessment or at least 2 points decrease from the double blind randomization baseline.</description>
        <time_frame>390 days was the maximum</time_frame>
        <population>Intent to treat population double blind (ITT-DB): included all randomized patients who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables: Alzheimer's Disease Assessment Scale-Cognitive and Disease Cooperative Study-Instrumental Activities of Daily Living.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Blind: Rivastigmine (10 cm^2)</title>
            <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
          <group group_id="O2">
            <title>Double Blind: Rivastigmine (15 cm^2)</title>
            <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Functional Decline as Measured by Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) Subscale During the Double Blind Period</title>
          <description>Functional decline was defined by either an at least 1 point decrease in the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-IADL) subscale score in a visit and confirmed by the following visit/assessment or at least 2 points decrease from the double blind randomization baseline.</description>
          <population>Intent to treat population double blind (ITT-DB): included all randomized patients who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables: Alzheimer's Disease Assessment Scale-Cognitive and Disease Cooperative Study-Instrumental Activities of Daily Living.</population>
          <units>Time in days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="85" upper_limit="113"/>
                    <measurement group_id="O2" value="91" lower_limit="85" upper_limit="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period</title>
        <description>Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part A. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. The TMT part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. The score represents the amount of time required to complete the task. Total values for TMT part A range between 0 and 300 seconds. A negative change indicates an improvement from baseline.</description>
        <time_frame>Baseline and week 48 of double blind period</time_frame>
        <population>Intent to treat population (ITT-DB): included all randomized patients with an assessment at baseline and week 48 who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables (ADAS-cog and ADCS-IADL).</population>
        <group_list>
          <group group_id="O1">
            <title>Double Blind: Rivastigmine (10 cm^2)</title>
            <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
          <group group_id="O2">
            <title>Double Blind: Rivastigmine (15 cm^2)</title>
            <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part A) at Week 48 of the Double Blind Period</title>
          <description>Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part A. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. The TMT part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. The score represents the amount of time required to complete the task. Total values for TMT part A range between 0 and 300 seconds. A negative change indicates an improvement from baseline.</description>
          <population>Intent to treat population (ITT-DB): included all randomized patients with an assessment at baseline and week 48 who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables (ADAS-cog and ADCS-IADL).</population>
          <units>Time in seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="62.57"/>
                    <measurement group_id="O2" value="16.3" spread="66.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period</title>
        <description>Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part B. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. TMT has two parts: Part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. Task requirements are similar for TMT-Part B except the person must alternate between numbers and letters. Total values for TMT part B range between 0 and 420 seconds. A negative change from baseline indicates an improvement in condition.</description>
        <time_frame>Baseline and week 48 of double blind period</time_frame>
        <population>Intent to treat population (ITT-DB): included all randomized patients with an assessment at baseline and week 48 who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables (ADAS-cog, ADCS-IADL).</population>
        <group_list>
          <group group_id="O1">
            <title>Double Blind: Rivastigmine (15 cm^2)</title>
            <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
          <group group_id="O2">
            <title>Double Blind: Rivastigmine (10 cm^2)</title>
            <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Attention and Executive Function as Assessed by the Trail Making Test (Part B) at Week 48 of Double Blind Period</title>
          <description>Change from baseline to week 48 in total time to perform Trail Making Test (TMT) part B. This test provides information on visual search, scanning, speed of processing, mental flexibility, and executive functions. TMT has two parts: Part A requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. Task requirements are similar for TMT-Part B except the person must alternate between numbers and letters. Total values for TMT part B range between 0 and 420 seconds. A negative change from baseline indicates an improvement in condition.</description>
          <population>Intent to treat population (ITT-DB): included all randomized patients with an assessment at baseline and week 48 who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables (ADAS-cog, ADCS-IADL).</population>
          <units>Time in seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
                <count group_id="O2" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="68.80"/>
                    <measurement group_id="O2" value="5.8" spread="65.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period</title>
        <description>Change from baseline to week 48 as assessed by the Neuropsychiatric Inventory (NPI)-10 total score. The scale consists of 10 domains that are rated for both frequency (range 1-4) and severity (range 1-3). A composite score for each domain is calculated (frequency x severity) which ranges from 1 to 12. There is a leading question for each item. If the symptom is not present then the frequency, severity and distress scores are not completed. In this case the score is 0 for the item. The sum of the composite scores yields the NPI-10 total score (range 0-120). A negative change in score indicates an improvement from baseline (symptom reduction).</description>
        <time_frame>Baseline and week 48 of double blind period</time_frame>
        <population>Intent to treat population double blind (ITT-DB): included all randomized patients with an assessment at baseline and week 48, who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables (ADAS-cog, ADCS-IADL).</population>
        <group_list>
          <group group_id="O1">
            <title>Double Blind: Rivastigmine (10 cm^2)</title>
            <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
          <group group_id="O2">
            <title>Double Blind: Rivastigmine (15 cm^2)</title>
            <description>Rivastigmine transdermal patch 15 cm^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Neuropsychiatric Inventory (NPI)-10 Score at Week 48 of Double Blind Period</title>
          <description>Change from baseline to week 48 as assessed by the Neuropsychiatric Inventory (NPI)-10 total score. The scale consists of 10 domains that are rated for both frequency (range 1-4) and severity (range 1-3). A composite score for each domain is calculated (frequency x severity) which ranges from 1 to 12. There is a leading question for each item. If the symptom is not present then the frequency, severity and distress scores are not completed. In this case the score is 0 for the item. The sum of the composite scores yields the NPI-10 total score (range 0-120). A negative change in score indicates an improvement from baseline (symptom reduction).</description>
          <population>Intent to treat population double blind (ITT-DB): included all randomized patients with an assessment at baseline and week 48, who received at least 1 dose of double blind study drug, and had at least 1 post-randomization assessment for both co-primary efficacy variables (ADAS-cog, ADCS-IADL).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="265"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="10.98"/>
                    <measurement group_id="O2" value="1.4" spread="11.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events</title>
        <time_frame>30 days after a maximum of 96 weeks treatment</time_frame>
        <population>The safety set included all patients who received at least one dose of study medication and who had at least one post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Open Label: Rivastigmine (5 cm^2 / 10 cm^2)</title>
            <description>Rivastigmine 5 cm^2 transdermal patch once a day during the first 4 weeks of open label treatment followed by rivastigmine 10 cm^2 transdermal patch once a day from week 4 to week 24, 36 or 48.</description>
          </group>
          <group group_id="O2">
            <title>Double Blind: Rivastigmine (10 cm^2)</title>
            <description>Rivastigmine transdermal patch 10 cm^2 and placebo to rivastigmine 15 cm^2 once daily for 48 weeks during the double blind period.</description>
          </group>
          <group group_id="O3">
            <title>Double Blind: Rivastigmine (15 cm^2)</title>
            <description>Rivastigmine transdermal patch 15c m^2 and placebo to rivastigmine 10 cm^2 once daily for 48 weeks during double blind period.</description>
          </group>
          <group group_id="O4">
            <title>Extended Open Label (10 cm^2)</title>
            <description>Rivastigmine 10 cm^2 transdermal patch once a day during 48 weeks open label treatment running in parallel to the double blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events, Serious Adverse Events and Discontinuations Due to Adverse Events</title>
          <population>The safety set included all patients who received at least one dose of study medication and who had at least one post-baseline safety assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1582"/>
                <count group_id="O2" value="283"/>
                <count group_id="O3" value="280"/>
                <count group_id="O4" value="457"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1135"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="210"/>
                    <measurement group_id="O4" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after a maximum of 96 weeks treatment</time_frame>
      <desc>The safety set included all patients who received at least one dose of study medication and who had at least one post-baseline safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Initial Open Label: Rivastigmine (5 cm^2 / 10 cm^2)</title>
          <description>Safety population Initial Open Label (Safety-IOL) - This population consisted of all patients who received at least 1 dose of study drug during the initial open label phase and had at least 1 post baseline safety assessment during the same phase.</description>
        </group>
        <group group_id="E2">
          <title>Double Blind: Rivastigmine (10 cm^2)</title>
          <description>Safety population Double Blind (Safety-DB) - This population included all patients who were randomized, received at least 1 dose of study drug during the double blind phase and had at least 1 post-randomization safety assessment during the double blind phase. Patients were analyzed according to treatment received.</description>
        </group>
        <group group_id="E3">
          <title>Double Blind: Rivastigmine (15 cm^2)</title>
          <description>Safety population Double Blind (Safety-DB) - This population included all patients who were randomized, received at least 1 dose of study drug during the double blind phase and had at least 1 post-randomization safety assessment during the double blind phase. Patients were analyzed according to treatment received.</description>
        </group>
        <group group_id="E4">
          <title>Extended Open Label: Rivastigmine (10 cm^2)</title>
          <description>Safety population Extended Open Label (Safety-EOL) - This population consisted of all patients who received at least 1 dose of study drug during the extended open label phase and had at least 1 post baseline safety assessment during the same phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="227" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Aortic valve calcification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Thyroid disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Complication of device removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cryptogenic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Mental status changes postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac enzymes increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Multiple system atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="732" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="112" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1582"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="283"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="280"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis</organization>
      <phone>862 778 8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

